^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Daurismo (glasdegib)

i
Company:
Pfizer
Drug class:
Hedgehog cell-signalling pathway inhibitor, SMO protein inhibitor
Phase 2
University of California, Irvine
Recruiting
Last update posted :
02/05/2024
Initiation :
02/19/2020
Primary completion :
06/01/2024
Completion :
09/30/2025
NPM1 • CEBPA
|
NPM1 mutation
|
Vyxeos (cytarabine/daunorubicin liposomal formulation) • Daurismo (glasdegib)
Phase 1/2
M.D. Anderson Cancer Center
Completed
Last update posted :
09/04/2023
Initiation :
12/27/2017
Primary completion :
02/04/2022
Completion :
02/04/2022
BCL2
|
Venclexta (venetoclax) • Bavencio (avelumab) • azacitidine • Mylotarg (gemtuzumab ozogamicin) • Daurismo (glasdegib) • ivuxolimab (PF-04518600)
Phase 1b
City of Hope Medical Center
Withdrawn
Last update posted :
06/09/2022
Initiation :
06/25/2022
Primary completion :
12/15/2023
Completion :
12/15/2023
FLT3 • ABL1 • BCR • IDH1 • AXL
|
IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836
|
Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • Bosulif (bosutinib) • decitabine • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Daurismo (glasdegib)
Phase 1b/2
Pfizer
Completed
Last update posted :
03/03/2020
Initiation :
06/27/2012
Primary completion :
01/03/2017
Completion :
03/04/2019
RUNX1
|
decitabine • daunorubicin • Daurismo (glasdegib)